<code id='EBA4FD37D3'></code><style id='EBA4FD37D3'></style>
    • <acronym id='EBA4FD37D3'></acronym>
      <center id='EBA4FD37D3'><center id='EBA4FD37D3'><tfoot id='EBA4FD37D3'></tfoot></center><abbr id='EBA4FD37D3'><dir id='EBA4FD37D3'><tfoot id='EBA4FD37D3'></tfoot><noframes id='EBA4FD37D3'>

    • <optgroup id='EBA4FD37D3'><strike id='EBA4FD37D3'><sup id='EBA4FD37D3'></sup></strike><code id='EBA4FD37D3'></code></optgroup>
        1. <b id='EBA4FD37D3'><label id='EBA4FD37D3'><select id='EBA4FD37D3'><dt id='EBA4FD37D3'><span id='EBA4FD37D3'></span></dt></select></label></b><u id='EBA4FD37D3'></u>
          <i id='EBA4FD37D3'><strike id='EBA4FD37D3'><tt id='EBA4FD37D3'><pre id='EBA4FD37D3'></pre></tt></strike></i>

          focus

          focus

          author:fashion    Page View:9
          In this photo illustration, Farxiga, Xarelto, Entresto, and Eliquis are made available to customers at the New City Halsted Pharmacy on August 29, 2023 in Chicago, Illinois. These are 4 of 10 prescription drugs that will be subject to Medicare price negotiations under the Inflation Reduction Act. The other drugs include Jardiance, Enbrel, Januvia, Imbruvica, Stelara and Fiasp.
          Scott Olson/Getty Images

          WASHINGTON  — The Biden administration is making its opening offers to pharmaceutical companies in its brand-new Medicare drug price negotiation program on Thursday, administration officials said. And that’s about all they said.

          The offers will not be made public unless a manufacturer chooses to publicly disclose information about the talks, a senior administration official said. Companies have until March 2 to either accept the government’s offer or propose a counteroffer. The Biden administration will publish the final prices by Sept. 1 of this year after the negotiation process ends. 

          advertisement

          The negotiated prices won’t take effect until 2026. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          DIEP, the 'gold standard' of breast reconstruction, is under threat
          DIEP, the 'gold standard' of breast reconstruction, is under threat

          AdobeIn1983,Iflewhomefromcollegetobewithmymotherasshewokeupfromamastectomy.Sheoptedoutofbreastrecons

          read more
          After decades in use, heart stents finally beat placebo
          After decades in use, heart stents finally beat placebo

          AdobePHILADELPHIA—Anewstudy,andthebolddoctorwholedit,couldresultinbigquestionsabouthowresearchersstu

          read more
          How one medical school became remarkably diverse
          How one medical school became remarkably diverse

          ThefirstclassattheUniversityofCalifornia,Davismedicalschool,in1972,waspredominantlywhiteandmale.Chri

          read more

          FDA cancer chief on how to get things done: ‘Don’t tell anybody'

          AdobeWASHINGTON—TheFoodandDrugAdministration’stopcancerdrugregulatordoesn’talwaysaskforpermissionbef